Bio-Techne (TECH) director’s linked account exercises options and sells 6,636 shares
Rhea-AI Filing Summary
BIO-TECHNE Corp director Amy E. Herr reported an exercise-and-sale transaction carried out through an account held by her significant other. On May 8, 2026, that account exercised 6,636 shares of BIO-TECHNE common stock at an exercise price of $47.60 per share and received the underlying shares.
On the same date, the same account sold 6,636 shares of common stock at a weighted average price of about $48.28 per share, leaving 200 indirect shares of common stock held by the significant other. Separately, Herr holds 2,680 shares of common stock directly, along with a range of stock options and restricted stock units that continue to represent additional exposure to BIO-TECHNE stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 6,636 shares ($5K approx. pre-tax spread)
Exercise and Sale
17 txns
Insider
Herr Amy E.
Role
Director
Sold
6,636 shs ($320K)
Approx. gross sale proceeds
$320K
Approx. exercise cost
$316K
Approx. pre-tax spread
$5K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 6,636 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,636 | $47.60 | $316K |
| Sale | Common Stock | 6,636 | $48.28 | $320K |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Restricted Stock Units | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 14,283 shares (Indirect, By significant other);
Common Stock — 200 shares (Indirect, By significant other);
Stock Option (Right to Buy) — 6,192 shares (Direct);
Restricted Stock Units — 1,447 shares (Indirect, By significant other);
Common Stock — 2,680 shares (Direct)
Footnotes (13)
- F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.19 to $48.31, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F2. This option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.
- F3. Fully vested.
- F4. Options to purchase 528 shares vest on 8/15/2023 and 8/15/2025; and options to purchase 524 shares vest on 8/15/2024 and 8/15/2026.
- F5. Options to purchase 271 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2026 and 8/15/2027.
- F6. Options to purchase 367 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- F7. Options to purchase 86 shares vest on each of 2/3/2026, 2/3/2027, 2/3/2028 and 2/3/2029.
- F8. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F9. 118 restricted stock units vest on 8/15/2026.
- F10. 160 restricted stock units vest on each of 8/15/2026 and 8/15/2027.
- F11. 38 restricted stock units vest on 2/3/2027 and 39 restricted stock units vest on 2/3/2028.
- F12. 311 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 310 restricted stock units vest on 8/15/2028.
- F13. Options to purchase 912 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 911 shares vest on 8/15/2028.
Key Figures
Shares sold: 6,636 shares
Weighted average sale price: $48.28 per share
Options exercised: 6,636 shares
+5 more
8 metrics
Shares sold
6,636 shares
Open-market or private sale on May 8, 2026
Weighted average sale price
$48.28 per share
Common stock sale range $48.19–$48.31
Options exercised
6,636 shares
Stock options exercised at $47.60 on May 8, 2026
Exercise price
$47.60 per share
Stock Option (Right to Buy) underlying 6,636 shares
Indirect common shares after sale
200 shares
Held by significant other following transactions
Direct common shares
2,680 shares
Direct BIO-TECHNE holdings following transactions
Largest indirect option block
4,472 underlying shares at $66.97
Stock Option (Right to Buy) expiring August 5, 2027
Largest direct option block
3,777 underlying shares at $60.96
Stock Option (Right to Buy) expiring October 30, 2035
Key Terms
weighted average price, Stock Option (Right to Buy), Restricted Stock Units, open-market sale, +1 more
5 terms
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)" with underlying common stock"
Restricted Stock Units financial
"security_title: "Restricted Stock Units" representing contingent rights to common stock"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
open-market sale financial
"transaction_action: "open-market sale" for common stock transaction code S"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
indirect ownership financial
"ownership_type: "indirect" with nature_of_ownership "By significant other""
FAQ
What insider transaction did BIO-TECHNE (TECH) disclose for Amy E. Herr?
BIO-TECHNE disclosed that an account held by director Amy E. Herr’s significant other exercised 6,636 stock options and sold 6,636 common shares on May 8, 2026. The filing classifies the sale as an open-market or private transaction.
What stock options were exercised in the BIO-TECHNE (TECH) Form 4 filing?
The filing shows 6,636 stock options with a $47.60 exercise price were exercised into BIO-TECHNE common shares on May 8, 2026. After this exercise, that specific option grant shows zero remaining derivative shares in the account of the significant other.
Does the BIO-TECHNE (TECH) Form 4 show remaining derivative awards for Amy E. Herr?
Yes. The filing lists several remaining stock option and restricted stock unit awards with exercise prices ranging from $53.60 to $120.46 and expiration dates through 2035, covering thousands of underlying BIO-TECHNE common shares held directly and indirectly.
AI-generated analysis. How Rhea-AI works. Not financial advice.
